Company Website:
http://www.antibethera.com
TORONTO -- (Business Wire)
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB:
ATBPF) filed its financial and operating results on Friday, February 15th
for the fiscal quarter ended December 31, 2018. The Company’s unaudited
fiscal Q3 2019 condensed interim consolidated financial statements and
MD&A are available on SEDAR.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s
technology involves linking a hydrogen sulfide-releasing molecule to an
existing drug to produce a patented, improved medicine. Antibe’s lead
drug ATB-346 targets the global need for a safer, non-addictive drug for
chronic pain and inflammation. ATB-352, the second drug in Antibe’s
pipeline, targets the urgent global need for a non-addictive analgesic
for treating severe acute pain, while ATB-340 is a GI-safe derivative of
aspirin. www.antibethera.com.
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the
sales and marketing of tissue regenerative products servicing the
orthopedic and dental marketplaces. Since its inception in 1997,
Citagenix has become an important source of knowledge and experience for
bone regeneration in the Canadian medical device industry. Citagenix is
active in 15 countries, operating in Canada through its direct sales
teams, and internationally via a network of distributor partnerships. www.citagenix.com.
Forward Looking Information
This news release includes certain forward-looking statements, which may
include, but are not limited to, the completion of financing
transactions and the licensing and development of drugs and medical
devices. Any statements contained herein that are not statements of
historical facts may be deemed to be forward-looking, including those
identified by the expressions "will", "anticipate", "believe", "plan",
"estimate", "expect", "intend", "propose" and similar expressions.
Forward-looking statements involve known and unknown risks and
uncertainties that could cause actual results, performance, or
achievements to differ materially from those expressed or implied in
this news release. Factors that could cause actual results to differ
materially from those anticipated in this news release include, but are
not limited to, the Company’s ability to secure additional financing,
its ability to execute its business strategy and successfully compete in
the market, and risks associated with drug and medical device
development generally. Antibe Therapeutics Inc. assumes no obligation to
update the forward-looking statements or to update the reasons why
actual results could differ from those reflected in the forward-looking
statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190215005591/en/
Contacts:
Antibe Therapeutics Inc.
Dan Legault
Chief Executive Officer
(416)
473 4095
dan.legault@antibethera.com
Source: Antibe Therapeutics Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.